Q3 EPS Estimate for Revelation Biosciences Lifted by Analyst

Revelation Biosciences, Inc. (NASDAQ:REVB) – Equities research analysts at Zacks Research increased their Q3 2026 earnings per share estimates for shares of Revelation Biosciences in a research note issued on Friday, August 7th. Zacks Research analyst B. Sorensen now anticipates that the company will post earnings of ($0.82) per share for the quarter, up from their prior forecast of ($0.83). The consensus estimate for Revelation Biosciences’ current full-year earnings is ($5.20) per share. Zacks Research also issued estimates for Revelation Biosciences’ Q4 2026 earnings at ($0.77) EPS, FY2026 earnings at ($5.17) EPS and FY2027 earnings at ($2.36) EPS.

Separately, Weiss Ratings lowered shares of Revelation Biosciences from a “sell (e+)” rating to a “sell (e)” rating in a report on Tuesday, July 28th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Revelation Biosciences presently has an average rating of “Sell”.

Revelation Biosciences Trading Down 1.8%

NASDAQ:REVB opened at $1.11 on Wednesday. The stock has a market cap of $4.34 million, a P/E ratio of -0.09 and a beta of -0.15. The stock’s 50-day moving average is $1.05 and its 200-day moving average is $1.22. Revelation Biosciences has a 1-year low of $0.88 and a 1-year high of $11.72.

Revelation Biosciences (NASDAQ:REVB) last posted its earnings results on Friday, August 7th. The company reported ($0.87) EPS for the quarter, beating the consensus estimate of ($0.88) by $0.01.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Sabby Management LLC lifted its holdings in Revelation Biosciences by 192.5% during the 4th quarter. Sabby Management LLC now owns 605,702 shares of the company’s stock worth $484,000 after buying an additional 398,651 shares during the period. Armistice Capital LLC grew its position in shares of Revelation Biosciences by 442.8% in the 4th quarter. Armistice Capital LLC now owns 434,272 shares of the company’s stock valued at $347,000 after buying an additional 354,272 shares during the last quarter. Finally, Geode Capital Management LLC acquired a new stake in shares of Revelation Biosciences in the fourth quarter valued at about $27,000. 12.80% of the stock is owned by institutional investors.

About Revelation Biosciences

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.